Fig. 7: Improved antitumor activity and antitumor immunity of anti-PD-1 antibody by R848@M2pep-MPs_AFP in DEN-induced autochthonous HCC mice.

a Schematic schedule for the anticancer experiment of combination of R848@M2pep-MPs_AFP and anti-PD-1 antibody in DEN-induced autochthonous HCC mice. b–e Tumor images (b), tumor weight (c), nodule numbers (d) and H&E staining of liver tissues (e) in DEN-induced autochthonous HCC mice at 30 weeks after treatment with R848@M2pep-MPs_AFP in the presence or absence of anti-PD-1 antibody at the anti-PD-1 antibody dosage of 5 mg kg⁻¹ and R848 dosage of 0.5 mg kg⁻¹ indicated in (a). Data are presented as means ± s.d. for (c, d). (n = 5 mice per group; one-way ANOVA followed by Tukey’s HSD post-hoc test). Scale bar: 5000 μm for (e). f Kaplan–Meier survival plot of DEN-induced autochthonous HCC mice after treatment indicated in (a). (n = 6 mice per group). g–r The numbers of CD80⁺ TAMs (g), CD86⁺ TAMs (h), MHC II⁺ TAMs (i), CD206⁺ TAMs (j), CD8⁺ T cells (k), CD8⁺Ki67⁺ T cells (l), CD8⁺CD69⁺ T cells (m), CD8⁺IFNγ⁺ T cells (n), CD8⁺GzmB⁺ T cells (o), CD8⁺PD-1⁺TCF-1⁺ T cells (p), CD8⁺PD-1⁺TCF-1^- T cells (q) and CD8⁺PD-1⁺TCF-1^-GzmB⁺ T cells (r) in tumor tissues of DEN-induced autochthonous HCC mice at 30 weeks after treatment indicated in (a). Data are presented as means ± s.d. (n = 5 mice per group; one-way ANOVA followed by Tukey’s HSD post-hoc test). Source data are provided as a Source Data file.